178 related articles for article (PubMed ID: 8847282)
41. Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Fontoura D; Oliveira-Pinto J; Tavares-Silva M; Leite S; Vasques-Nóvoa F; Mendes-Ferreira P; Lourenço AP; Leite-Moreira AF
Rev Port Cardiol; 2014 Apr; 33(4):213-22. PubMed ID: 24780128
[TBL] [Abstract][Full Text] [Related]
42. A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Noguchi Y; Sudoh K; Sasamata M; Miyata K
Vascul Pharmacol; 2005 Jun; 43(1):40-6. PubMed ID: 15975532
[TBL] [Abstract][Full Text] [Related]
43. Exogenous ghrelin attenuates the progression of chronic hypoxia-induced pulmonary hypertension in conscious rats.
Schwenke DO; Tokudome T; Shirai M; Hosoda H; Horio T; Kishimoto I; Kangawa K
Endocrinology; 2008 Jan; 149(1):237-44. PubMed ID: 17916633
[TBL] [Abstract][Full Text] [Related]
44. Docosahexaenoic acid inhibits development of hypoxic pulmonary hypertension: in vitro and in vivo studies.
Yan J; Chen R; Liu P; Gu Y
Int J Cardiol; 2013 Oct; 168(4):4111-6. PubMed ID: 23907044
[TBL] [Abstract][Full Text] [Related]
45. Punicalagin Prevents Hypoxic Pulmonary Hypertension via Anti-Oxidant Effects in Rats.
Shao J; Wang P; Liu A; Du X; Bai J; Chen M
Am J Chin Med; 2016; 44(4):785-801. PubMed ID: 27222062
[TBL] [Abstract][Full Text] [Related]
46. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
47. Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.
Rafikova O; Rafikov R; Kumar S; Sharma S; Aggarwal S; Schneider F; Jonigk D; Black SM; Tofovic SP
Free Radic Biol Med; 2013 Mar; 56():28-43. PubMed ID: 23200808
[TBL] [Abstract][Full Text] [Related]
48. Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells.
Maruyama H; Dewachter C; Sakai S; Belhaj A; Rondelet B; Remmelink M; Vachiéry JL; Naeije R; Dewachter L
Life Sci; 2016 Aug; 159():111-115. PubMed ID: 27188586
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of endothelin-1 and hypoxia-induced pulmonary pressor responses in the rat by a novel selective endothelin-A receptor antagonist, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe.
Yan LD; Kong LL; Yong Z; Dong HJ; Chi MG; Pan XF; Zhang C; Liang YJ; Gong ZH; Liu KL
J Cardiovasc Pharmacol; 2010 Sep; 56(3):246-54. PubMed ID: 20531217
[TBL] [Abstract][Full Text] [Related]
50. Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan.
Fraser TB; Mangos GJ; Turner SW; Whitworth JA
Clin Exp Pharmacol Physiol; 1999 Aug; 26(8):628-33. PubMed ID: 10474778
[TBL] [Abstract][Full Text] [Related]
51. Cardioprotective and vasomotor effects of HO activity during acute and chronic hypoxia.
Hartsfield CL; McMurtry IF; Ivy DD; Morris KG; Vidmar S; Rodman DM; Fagan KA
Am J Physiol Heart Circ Physiol; 2004 Nov; 287(5):H2009-15. PubMed ID: 15217799
[TBL] [Abstract][Full Text] [Related]
52. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.
Morrell NW; Morris KG; Stenmark KR
Am J Physiol; 1995 Oct; 269(4 Pt 2):H1186-94. PubMed ID: 7485548
[TBL] [Abstract][Full Text] [Related]
53. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
Huh JW; Kim SY; Lee JH; Lee YS
Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997
[TBL] [Abstract][Full Text] [Related]
54. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
Voelkel NF; Tuder RM; Bridges J; Arend WP
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
[TBL] [Abstract][Full Text] [Related]
55. Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets.
Fike CD; Zhang Y; Kaplowitz MR
J Appl Physiol (1985); 2005 Aug; 99(2):670-6. PubMed ID: 15802364
[TBL] [Abstract][Full Text] [Related]
56. Effects of ET-A receptor blockade on eNOS gene expression in chronic hypoxic rat lungs.
Blumberg FC; Wolf K; Arzt M; Lorenz C; Riegger GA; Pfeifer M
J Appl Physiol (1985); 2003 Feb; 94(2):446-52. PubMed ID: 12391096
[TBL] [Abstract][Full Text] [Related]
57. The somatostatin analog angiopeptin does not reduce chronic hypoxic pulmonary hypertension in rats.
Sidney EJ; Hampl V; Nelson DP; Archer SL; Foegh ML; Cathapermal SS; Weir EK
Proc Soc Exp Biol Med; 1996 Oct; 213(1):43-9. PubMed ID: 8820822
[TBL] [Abstract][Full Text] [Related]
58. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
Schroll S; Arzt M; Sebah D; Nüchterlein M; Blumberg F; Pfeifer M
Respir Physiol Neurobiol; 2010 Jan; 170(1):32-6. PubMed ID: 19931426
[TBL] [Abstract][Full Text] [Related]
59. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure.
Jiang BH; Tardif JC; Shi Y; Dupuis J
Eur Respir J; 2011 Mar; 37(3):578-86. PubMed ID: 20595149
[TBL] [Abstract][Full Text] [Related]
60. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
Kim H; Yung GL; Marsh JJ; Konopka RG; Pedersen CA; Chiles PG; Morris TA; Channick RN
Eur Respir J; 2000 Apr; 15(4):640-8. PubMed ID: 10780753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
